← American Pharmacists Association (APhA)
FDANonrulemakingFDA-2019-N-1132

The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products; Date for Public Hearing; Request for Comments

RIN
—
Last modified
Jun 25, 2019
Comment window
closed 2615d ago
American Pharmacists Association (APhA) filings
1

Activity

American Pharmacists Association (APhA) filed 1 comment on this docket between Jun 5, 2019 and Jun 5, 2019. 5 other organizations filed here. The comment window closed 2615d ago.

What American Pharmacists Association (APhA) filed (1)

Jun 5, 2019· Comment from American Pharmacists Association (APhA) et al· FDA-2019-N-1132-0327

Please see the attached joint comments of the American Pharmacists Association, the National Association of Chain Drug Stores, and the National Community Pharmacists Association on the topic of promoting access to biosimilar and interchangeable insulin products. We thank the Food and Drug Administration for considering our perspectives on this matter.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (5)

See everyone who commented →